CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
MultiplexDX is developing Multiplex8+, a precise diagnostic test for breast cancer that combines innovative technologies to reduce misdiagnosis. This test aims to personalize treatment plans based on individual patient profiles, improving outcomes.
Breast cancer (BCa) is the most common cancer in women worldwide with 2.1M new cases diagnosed annually, and this number is expected to double in 2030.
However, today’s diagnostic tests lack precision and, as a result, many BCa patients are misdiagnosed then treated inaccurately, putting their lives at risk while creating undue problems for families and healthcare systems.
MultiplexDX (a leading Slovak biotechnology company) proposes a personalized and precise diagnostic test for early and late…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
